Editor’s Letter
Fourth and final issue of GaBI Journal’s fourth volume
This last issue of 2015 starts with a Commentary by Drs Christoph Baumgärtel and Brian Godman concerning the approval of generic versions of narrow therapeutic margin products; including immunosuppressant drugs.… Read More »
Latest features in GaBI Journal, 2015, Issue 3
This issue of the journal contains a number of manuscripts that discuss proposals to simplify the evaluation of, and therefore decrease the cost of developing, follow-on biological products. These controversial… Read More »
What to look forward to in GaBI Journal, 2015, Issue 2
This entire issue of the GaBI Journal could be titled ‘World News’ since it contains manuscripts describing global generics and biosimilar activities. The Commentary by Leng et al. describes regulatory… Read More »
Editor’s introduction to the initial issue of the fourth volume of GaBI Journal
This first 2015 GaBI Journal issue (fourth volume of the journal) is being published soon after the first US biosimilar approval and it contains a number of articles that illustrate… Read More »
Fourth and final issue of GaBI Journal’s third volume
The interest in the development, regulatory approval, use, and post-marketing surveillance of generic and biosimilar pharmaceutical products continues to increase; as illustrated by the tremendous number of views (over 1,028,324… Read More »
Latest features in GaBI Journal, 2014, Issue 3
This issue of the GaBI Journal begins with editorial comments from our Deputy Editor-in-Chief Dr Robin Thorpe concerning the Review Article by Azevedo et al. covering biosimilar regulations and their… Read More »
What to look forward to in GaBI Journal, 2014, Issue 2
As mentioned previously, non-biological complex drugs (NBCDs) continue to raise important regulatory and practice issues. This issue of the GaBI Journal contains a number of manuscripts dealing with these products… Read More »
Editor’s introduction to the initial issue of the third volume of GaBI Journal
This issue of the GaBI Journal begins with editorial comments from our Deputy Editor-in-Chief Dr Robin Thorpe concerning the Review Article by Azevedo et al. covering biosimilar regulations and their… Read More »
GaBI Journal publishes four issues in 2013
This issue marks the forth and final issue of the second year’s edition of the GaBI Journal. The journal has grown rapidly through the combined efforts of the publisher and… Read More »
Latest features in GaBI Journal, 2013, Issue 3
The GaBI Journal again contains manuscripts covering a wide range of pertinent topics. In an Editorial, Dr Gianluigi Casadei reviews Italy’s final position paper on biosimilars including the new price… Read More »